Ralliant (NYSE:RAL) Issues FY 2026 Earnings Guidance

Ralliant (NYSE:RAL) updated its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 2.760-2.900 for the period, compared to the consensus EPS estimate of 2.650. The company issued revenue guidance of $2.3 billion-$2.3 billion, compared to the consensus revenue estimate of $2.2 billion. Ralliant also updated its Q3 2026 guidance to 0.720-0.780 EPS.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on RAL shares. Vertical Research lowered shares of Ralliant from a “buy” rating to a “hold” rating and set a $65.00 target price for the company. in a research report on Wednesday, May 27th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Ralliant in a research note on Monday, May 4th. Oppenheimer increased their price objective on shares of Ralliant from $50.00 to $65.00 and gave the company an “outperform” rating in a report on Wednesday, May 13th. Zacks Research upgraded shares of Ralliant from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, June 30th. Finally, Evercore assumed coverage on Ralliant in a report on Tuesday, June 9th. They set an “outperform” rating and a $80.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $75.70.

Ralliant Price Performance

Shares of NYSE RAL opened at $65.78 on Friday. Ralliant has a twelve month low of $37.27 and a twelve month high of $75.41. The company has a current ratio of 1.52, a quick ratio of 1.05 and a debt-to-equity ratio of 0.75. The company has a market capitalization of $7.36 billion and a price-to-earnings ratio of -6.06. The firm has a 50-day moving average of $67.20 and a two-hundred day moving average of $54.34.

Ralliant (NYSE:RAL) last announced its quarterly earnings data on Thursday, July 30th. The company reported $0.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.63 by $0.05. Ralliant had a negative net margin of 56.38% and a positive return on equity of 14.97%. The company had revenue of $567.80 million for the quarter. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. As a group, analysts expect that Ralliant will post 2.83 earnings per share for the current fiscal year.

Ralliant Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 23rd. Investors of record on Monday, June 8th were issued a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date was Monday, June 8th. Ralliant’s dividend payout ratio (DPR) is presently -1.83%.

Ralliant News Roundup

Here are the key news stories impacting Ralliant this week:

• Positive Sentiment: Quarterly results exceeded expectations: Ralliant reported second-quarter revenue of approximately $568 million, up 13% year over year, and adjusted EPS of $0.68 versus the $0.63 consensus estimate. Adjusted net earnings were $76 million, while net earnings were $57 million. Ralliant Reports Second Quarter 2026 Results and Raises Full Year Guidance
• Positive Sentiment: Full-year and third-quarter outlooks topped consensus: Ralliant guided third-quarter EPS to $0.72-$0.78 and revenue to $570 million-$590 million, above analyst estimates of $0.68 and $556.4 million, respectively. Full-year 2026 adjusted EPS guidance was raised to $2.76-$2.90 from an analyst consensus of $2.65, with revenue expected around $2.25 billion-$2.30 billion. Ralliant forecasts 2026 revenue and productivity savings
• Positive Sentiment: Cost-reduction efforts could support future margins: Ralliant’s enterprise productivity program is targeting $50 million-$60 million in annualized run-rate savings by 2028, providing a potential boost to earnings and cash flow.
• Positive Sentiment: Analysts raised targets: Citigroup increased its target to $82 and initiated a “buy” rating, Truist raised its target to $82 while reaffirming “buy,” and RBC lifted its target to $73 while maintaining a “sector perform” rating. These targets imply meaningful upside from the recent trading level. Benzinga analyst actions
• Neutral Sentiment: Trading volatility increased: RAL experienced a temporary limit-up/limit-down trading pause during the earnings session, signaling elevated short-term volatility rather than a fundamental change in the business.
• Negative Sentiment: Valuation and execution risks remain: Despite the adjusted earnings beat, investors may continue to focus on Ralliant’s reported profitability, integration or productivity-program execution, and the gap between the stock’s recent price and analyst targets.

Institutional Investors Weigh In On Ralliant

Large investors have recently modified their holdings of the stock. Palisade Asset Management LLC acquired a new stake in shares of Ralliant during the third quarter worth $26,000. BOKF NA acquired a new position in shares of Ralliant in the 3rd quarter valued at $29,000. Wilmington Savings Fund Society FSB acquired a new position in shares of Ralliant in the 3rd quarter valued at $30,000. EverSource Wealth Advisors LLC purchased a new position in Ralliant in the 2nd quarter worth about $39,000. Finally, NewEdge Advisors LLC acquired a new stake in Ralliant during the 2nd quarter worth about $43,000.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.